Keywords
Schizophrenia ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

363 Search results.

Eligibility Schizophrenia NCT01879709

- 9/28/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Yoga as Cognitive Remediation in Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01879709

Measurement Instrument Database for the Social Science (MIDSS) - The Perceived Family Burden Scale (PFBS)

- 7/20/20 - 1 form, 1 itemgroup, 49 items, 1 language
Itemgroup: THE PERCEIVED FAMILY BURDEN SCALE
Levene, J. E., Lancee, W. J., Seeman, M. V. (1996). The Perceived Family Burden Scale (PFBS). Measurement Instrument Database for the Social Science. Retrieved 20.07.2020, from www.midss.ie Key references: Levene, J. E., Lancee, W. J., Seeman, M. V. (1996). The perceived family burden scale: measurement and validation. Schizophrenia Research, 22(2), 151–157. Primary use / Purpose: The Perceived Family Burden Scale (PFBS) is a 24-item questionnaire rated on a 5 point Likert type scale. It contains an additional choice for each of the items where the user can also identify that the particular symptom is not present. The purpose of the scale is to measure the burden of schizophrenia on the family of a patient. Background: Many scales have been developed for the classification of, and quality of life associated with, mental illness. However, less attention has been paid to the families of mentally ill patients who can also experience difficulty. Many family members in this situation have to take on fulltime roles as caregivers, or at the very least experience they a heightened concern for the well-being of the patient and themselves. To measure this possible burden in relation to schizophrenia, in particular, the Perceived Family Burden Scale (PFBS) was developed. Psychometrics: The psychometric properties of the Perceived Family Burden Scale (PFBS) are discussed in Levene, Lancee, & Seeman, (1996). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.399 INSTRUCTIONS FOR RATERS The Perceived Family Burden Scale is rated on a five point scale, with a range from 0 to 5. Ratings: 0 = the behaviour isn’t present and doesn’t bother the relative 1 = the behaviour is present and doesn’t bother the relative 2 = the behaviour is present and bothers the relative “a little”. 3 = the behaviour is present and bothers the relative “considerably”. 4 = the behaviour is present and bothers the relative “a great deal”. In our study, we derived three variables which were used in the validation study: 1) the total score 2) an “objective score” (the number of problem behaviours identified by the informant). 3) a “subjective score” (the extent to which the behaviour “bothers” the relative).

Eligibility Schizophrenia NCT02086162

- 4/19/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Randomized Controlled Trial (RCT) of a Motivational Decision Support System; ODM derived from: https://clinicaltrials.gov/show/NCT02086162

Eligibility Relapse Schizophrenia NCT01885923

- 3/5/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A RCT Study in Schizophrenia Relapse Prevention; ODM derived from: https://clinicaltrials.gov/show/NCT01885923

Eligibility Schizophrenia NCT01685931

- 12/31/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics; ODM derived from: https://clinicaltrials.gov/show/NCT01685931

Eligibility Genetic High Risk for Schizophrenia NCT01943175

- 12/20/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01943175

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Concomitant Medications

- 12/18/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Administrative documentation, Concomitant Agent
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Non-Serious Adverse Events (AE)

- 12/18/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Administrative documentation, Non-serious Adverse Event
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Day 1 RE-TEST

- 12/18/19 - 1 form, 18 itemgroups, 81 items, 1 language
Itemgroups: Administrative documentation, Allen test, Vital signs, Pulmonary function tests, 12 lead ECG, Holter Electrocardiography, Positron-Emission Tomography, Pre-dose, Pharmacokinetic aspects - Blood, Randomization, Numbers, Therapeutic procedure, Confirmation, Experimental drug, Positron-Emission Tomography, Post-dose, Physical Examination, Post-dose, Vital signs, Post-dose, Laboratory Procedures, Post-dose, Hematology finding, Laboratory Procedures, Post-dose, Chemistry, Clinical, Urinalysis, Post-dose, Laboratory Procedures, Post-dose, Renal function
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Investigator's Signature

- 12/18/19 - 1 form, 2 itemgroups, 4 items, 1 language
Itemgroups: Administrative documentation, Investigator Signature
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Investigator Comment Log

- 12/18/19 - 1 form, 2 itemgroups, 3 items, 1 language
Itemgroups: Administrative documentation, Clinical Investigators, Comment
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Serious Adverse Event (SAE)

- 12/18/19 - 1 form, 13 itemgroups, 44 items, 1 language
Itemgroups: Administrative documentation, Serious Adverse Event, Serious Adverse Event, Seriousness of Adverse Event, Serious Adverse Event, Demography, Serious Adverse Event, Relationships, Experimental drug, Serious Adverse Event, Etiology aspects, Serious Adverse Event, Disease, Serious Adverse Event, Risk factors, Serious Adverse Event, Concomitant Agent, Serious Adverse Event, Experimental drug, Details, Serious Adverse Event, Diagnostic Procedure, Serious Adverse Event, Comment, Serious Adverse Event, Investigator Signature
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.